Search
Protalix Biotherapeutics Inc
PLXAdd to Watchlist
2.640USD
-0.090-3.30%
Close 09-11 16:00（ET）
213.51MMarket Cap
13.72P/E TTM
After-hours 18:30 (ET)2.640USD-0.015-0.56%
After-hours 18:30 (ET)Protalix Biotherapeutics Inc (PLX) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Protalix Biotherapeutics Inc in the past month.
Buy
0 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
11.000USD+311.99%
PLX Analyst Recommendation Trends
In the current month, PLX has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PLX average Analyst price target in the last month is 11.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
PLX Analyst Rating for Peer Comparison
Updated: Sep 11, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Regeneron Pharmaceuticals Inc
REGN
6
15
11
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Pfizer Inc
PFE
5
6
19
1
1
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, PLX EPS is projected to reach -0.030 in FY2026Q3, following reported EPS of 0.047 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.01
-0.01
-0.01
-0.03
-0.01
Actual
-0.07
0.23
0.05
--
--
Surprise
-1484.40%
+2394.00%
+572.20%
--
--
FAQs
What is Protalix Biotherapeutics Inc's expected revenue for the next quarter?
Protalix Biotherapeutics Inc's expected revenue is 13.36M.
What is Protalix Biotherapeutics Inc's price target?
Analysts forecast that Protalix Biotherapeutics Inc's price target is USD 11.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 10.00.
How have Protalix Biotherapeutics IncPLX's recent earnings per share performed?
The market expectation was USD 0.05, while Protalix Biotherapeutics IncPLX's earnings per share (EPS) for the previous quarter was USD 0.23. EPS for the next quarter is expected at USD -0.03.
What is the analyst rating for Protalix Biotherapeutics Inc?
Based on the ratings of Protalix Biotherapeutics Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.